For the Inventor, By the Inventor

Enter assignee name

Xintela Ab

USPTO Granted Patents = 15

% Expired Patents = 40.0

CIPO Patents = 3

EPO Patents = 5

Trademarks = 2

Forward Citations = 24

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Evy Lundgren-Åkerlund (8 out of 10 patents)

Evy Lundgren Åkerlund (4 out of 4 patents)

Katarzyna Chmielarska Masoumi (3 out of 3 patents)

4. Jan Talts (2 out of 6 patents)

5. Ramiro Gisler (1 out of 1 patent)

6. Evy Lundgren-Ãkerlund (1 out of 1 patent)

7. Evy Lundgren-Äkerlund (1 out of 1 patent)

8. Christina Uvebrant (1 out of 1 patent)

9. Evy Lundgren Åkerlund (1 out of 1 patent)

10. Moustafa Elmasry (1 out of 1 patent)

11. Hooi Ching Lim (1 out of 1 patent)

12. Ahmed Elserafy (1 out of 1 patent)

13. Folke Sjöberg (1 out of 1 patent)

14. Evy Lundgren Akerlund (0 patent)

15. Evy Lundgren-Akerlund (0 patent)

15 patents: Sort by Forward Citations

1. 12599633 - Mesenchymal stem cells for use in the treatment of skin defects (2026-04-14),

2. 12247222 - Quality assurance of chondrocytes (2025-03-11),

3. 11725188 - Quality assurance of chondrocytes (2023-08-15),

4. 11517593 - Prevention and treatment of bone and cartilage damage or disease (2022-12-06),

5. 10994022 - Detection and treatment of malignant tumours in the CNS (2021-05-04),

6. 10781424 - Quality assurance of chondrocytes (2020-09-22),

7. 10087253 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2018-10-02),

8. 10081666 - Integrin heterodimer and a subunit thereof (2018-09-25),

9. 9365649 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2016-06-14),

10. 8895253 - Integrin heterodimer and a subunit thereof (2014-11-25),

11. 8563255 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2013-10-22),

12. 8105791 - Marker for stem cells and its use (2012-01-31),

13. 8048991 - Antibody to an integrin heterodimer and/or a subunit thereof (2011-11-01),

14. 8012696 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2011-09-06),

15. 7749710 - Marker for stem cells and its use (2010-07-06),

Xintela AB is a Swedish biotech company that specializes in regenerative medicine and cancer therapies. They focus on developing innovative treatments using stem cells and antibodies to target and repair damaged tissues. Xintela aims to revolutionize the healthcare industry with their cutting-edge research and therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

15 Patents

#30 in Lund

#430 in Sweden

#39,822 in the World

Xintela Ab

Forward Citations = 24

12 inventors:

Evy Lundgren-Åkerlund (8 out of 10 patents)

Evy Lundgren Åkerlund (4 out of 4 patents)

Katarzyna Chmielarska Masoumi (3 out of 3 patents)

4. Jan Talts (2 out of 6 patents)

5. Ramiro Gisler (1 out of 1 patent)

Please report any incorrect information to [email protected]

Loading…